EQRx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 362
- Market Cap
- -
- Website
- http://www.eqrx.com
A Study of Lerociclib in Participants With Advanced Breast Cancer
Phase 2
Terminated
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- EQRx, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05085002
- Locations
- 🇺🇸
Cancer Specialists of North Florida, Jacksonville, Florida, United States
🇺🇸Oregon Oncology Specialists, Salem, Oregon, United States
🇺🇸Tranquil Clinical Research, Webster, Texas, United States
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations
Phase 1
Completed
- Conditions
- NSCLCHealthy VolunteersPharmacokinetics
- Interventions
- Drug: aumolertinib
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- EQRx, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04969965
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
🇳🇿New Zealand Clinical Research, Auckland, New Zealand
© Copyright 2025. All Rights Reserved by MedPath